Skip to main content

Table 2 FICHCOMP anticancer drugs prescribed during the study

From: Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

Any FICHCOMP drug Patients % N° of stays %
N = 6959 100% N = 42,220 100%
Pemetrexed 5464 78,5% 29,149 69.0%
Bevacizumab 1124 16,2% 8223 19.5%
Docetaxela 1605 23,1% 5656 13.4%
Topotecan 350 5,0% 2245 5.3%
Gemcitabinea 280 4,0% 1035 2.5%
  1. Patients could be prescribed more than one extra-DRG drug, so these frequency counts are not mutually exclusive
  2. aThese drugs were withdrawn from the special funding list (liste en sus) during the data collection period